Author:
Delli Florentina-Silvia, ,Sotiriou Elena,Vakirlis Efstratios,Ioannides Demetrios
Abstract
<abstract>
<p>Autoimmune blistering skin disorders are rare. According to direct immunofluorescence studies, three categories are described: pemphigus group, pemphigoid group and dermatitis herpetiformis. Among these diseases, bullous pemphigoid is the most common. Patients with typical bullous pemphigoid disease are usually elderly and have many comorbidities. Considering that topical and systemic corticosteroids are the first choice therapy, these patients also have increased morbidity and risk of death. The main characteristic of bullous pemphigoid as an acquired autoimmune blistering disease is the formation of autoantibodies against hemidesmosomal antigens BP180 and BP230. Although IgG autoantibodies predominate within the plasma and skin of BP patients, some features of the disease cannot be explained solely by IgG-mediated mechanisms. Epitope spreading phenomena, immunoglobulin class switch and the relevance of IgM and IgE autoantibodies are discussed in this article.</p>
</abstract>
Publisher
American Institute of Mathematical Sciences (AIMS)
Reference23 articles.
1. Fairley JA, Heintz PW, Neuburg M, et al. (1995) Expression pattern of the bullous pemphigoid-180 antigen in normal and neoplastic epithelia. Brit J Dermatol 133: 385-391.
2. Künzli K, Favre B, Chofflon M, et al. (2016) One gene but different proteins and diseases: the complexity of dystonin and bullous pemphigoid antigen 1. Exp Dermatol 25: 10-16.
3. Chanprapaph K, Ounsakul V, Pruettivorawongse D, et al. (2019) Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: A prospective cohort study. Asian Pac J Allergy Immunol 10: 12932.
4. Ludwig RJ (2019) Bullous pemphigoid: more than one disease? J Eur Acad Dermatol 33: 459-460.
5. Di Zenzo G, Thoma-Uszynski S, Calabresi V, et al. (2011) Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 131: 2271-2280.